Pioglitazone hydrochloride sustained-release dropping pill and preparation method thereof

Abstract

The invention discloses to a drug compound for treating diabetes and particularly relates to a drug compound oral pharmaceutical formulation adopting pioglitazone as the ingredient. The drug compound aims to supplement the deficiency of the prior oral pharmaceutical formulation used for treating Type-2 Diabetes and provide a drug compound oral pharmaceutical formulation, sustained-release pioglitazone dropping pill which has high bioavailability, controllable release time, long-acting effect, low frequency of drug taking, steady plasma concentration, low cost and absence of contamination during the production. The sustained-release pioglitazone dropping pill adopts pioglitazone as the chemical ingredient and is prepared jointly with the medicinal carriers of hydrophilic frame ingredients and hydrophobic frame ingredients used as the stroma.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating diabetes, in particular to a sustained-release oral preparation of the pharmaceutical composition prepared from pioglitazone hydrochloride as a raw material. Background technique [0002] Diabetes mellitus (Diabetes mellitus) is a syndrome of glucose, protein and lipid metabolism disorders caused by the destruction of insulin tissue in the body or the inability of the body to properly utilize insulin. If the metabolic disorder is not well controlled, it can lead to chronic complications of the eyes, kidneys, nerves, blood vessels, heart, and organs, resulting in blindness, lower limb gangrene, uremia, stroke or myocardial infarction, and even life-threatening. [0003] Type II diabetes mellitus (NIDDM) is the third largest disease in the world - the most common type of diabetes. Its main cause is insulin resistance, so long-term use of insulin therapy is not suitable, and the adverse re...

AI Technical Summary

Problems solved by technology

[0010] Due to reasons such as preparation technology, the oral preparations of most drugs all have long dissolution time, low dissolution rate, poor absorption, unstable blood drug concentration, many times of taking medicine, hepatic and intestinal first-pass effect and bioavailability after taking. Low-level problems, which affect the efficacy of the drug and directly affect the therapeutic effect

In addition, conventional oral dosage forms, such as tablets, capsules, etc., will produce relatively large dust pollution due to the granulation process in the preparation process, which will cause harm to the health of the staff to a certain extent, and will also cause harm to the human body. some pollution to the environment

Furthermore, the production process of conventional oral preparations is complicated and the production cost is high, so that the cost of medication for patients is also increased, which is not conducive to improving the ability of patients to seek medical treatment, and is also not conducive to improving the overall health level of society.

[0011] The Chinese invention patent discloses a pioglitazone hydrochloride dripping pill with the patent number 200510066001.7 and its preparation method. Although this patent overcomes the shortcomings of oral preparations such as tablets and capsules, it has the advantages of high bioavailability, rapid drug release, and rapid effect. , but it has many times of taking medicine every day, and it does not have long-acting function

Images